Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD)

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

The drugmaker’s first-quarter revenue of $41.1 million came in well below the consensus estimate of $56.7 million, attributed to changes in AbbVie’s gross-to-net rebate reserves.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Ironwood must run a new Phase 3 trial after FDA talks, delaying its SBS drug approval despite strong results from prior studies.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

IRWD stock results show that Ironwood Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

IRWD stock results show that Ironwood Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

As the stock market corrects, focusing on stable investments is crucial. This is why you should steer clear of these biotech stocks to avoid.